KR810001047B1 - Method for preparing cyclic acetal derivative of sterylglucoside - Google Patents
Method for preparing cyclic acetal derivative of sterylglucoside Download PDFInfo
- Publication number
- KR810001047B1 KR810001047B1 KR7701265A KR770001265A KR810001047B1 KR 810001047 B1 KR810001047 B1 KR 810001047B1 KR 7701265 A KR7701265 A KR 7701265A KR 770001265 A KR770001265 A KR 770001265A KR 810001047 B1 KR810001047 B1 KR 810001047B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- general formula
- sterylglucoside
- glucopyranoside
- cyclic acetal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Steroid Compounds (AREA)
Abstract
내용 없음.No content.
Description
본 발명은 다음의 일반식(I)The present invention is the following general formula (I)
(식중 R은-시토스테릴기, 캄페스테릴기, 스티그마스테릴기 혹은 이들의 혼합물을 표시하거나, 또는 코레스테릴기를 표시한다.(Where R is -Represent a cytosteryl group, a camphorsteryl group, a stigmasteryl group or a mixture thereof, or a cholesteryl group.
R1는 H 또는 메틸기를 표시한다)으로 표시되는 2,3-옥시드 알킬리덴-4,6-알킬리덴--D-글루코피라노시드 유도체의 제조방법에 관한 것이다. 본 화합물은 문헌에 미재인 신규물질로서, 우수한 혈관보강작용, 지혈작용, 항염증작용을 나타내고, 독성도 또 지극히 약하여 의약품으로서 유용하다. 본 발명의 화합물(I)은 여러가지 방법으로 합성할 수 있으나 특히 다음 방법이 바람직하다.R 1 represents H or a methyl group), 2,3-oxide alkylidene-4,6-alkylidene- A method for producing a -D-glucopyranoside derivative. This compound is a novel substance which is unknown in the literature, and has excellent vascular reinforcement, hemostatic action, and anti-inflammatory action, and its toxicity is extremely weak, so it is useful as a medicine. The compound (I) of the present invention can be synthesized by various methods, but the following method is particularly preferable.
즉 다음의 일반식(II)That is, the following general formula (II)
(식중 R은 상기와 같음)으로 표시되는 화합물로서 일반식(Ⅱ)(Wherein R is as defined above) as a compound represented by the general formula (II)
(R1CHO)n (Ⅱ)(R 1 CHO) n (II)
(식중 R1는 H 또는 메틸기를 표시하고, n은 3이상의 정수를 표시한다)으로 표시되는 파라포름알데히드, 파라알데히드등의 알데히드류를 산촉매의 존재하에서 반응시켜서 목적으로 하는 (I)은 합성시킨다.The target (I) is synthesized by reacting aldehydes such as paraformaldehyde and paraaldehyde in which R 1 represents H or a methyl group and n represents an integer of 3 or more in the presence of an acid catalyst. .
이 방법에 있어서 반응에 사용하는 과잉의 알데히드류 그 자체가 용매로 되는 경우도 있으나 필요하면 벤젠과 같은 유기용매를 첨가하여 행할수도 있다. 산촉매로서는 통상황산이 사용된다. 필요하면 탈수제를 첨가하여도 좋다.In this method, the excess aldehydes used in the reaction may be used as a solvent, but if necessary, it may be performed by adding an organic solvent such as benzene. Sulfuric acid is usually used as the acid catalyst. If necessary, a dehydrating agent may be added.
다음에 실시예로 상세히 설명하지만 본 발명은 이들 실시예만으로 한정되는 것은 아니다.The present invention will be described in detail with reference to the following Examples, but the present invention is not limited to these Examples.
[실시예 1]Example 1
스테릴-2,3-옥시도에틸리덴-4,6-에틸리덴--D-글루코피라노시드, 스테릴--D-글루코피라노시드(대두레시틴으로부터 추출제조한 스테릴--D-글루코피라노시드로서, 그 스테롤의 조정은-시토스테롤 60%, 스티그마스테롤 20%, 캄페스테롤 20%이다) 10.0g을 300㎖의 프라스코에 넣어서 파라알데히드 100㎖를 첨가하여 현탁액으로 한다. 농황산 한 방울을 첨가하여 실온으로 24시간 교반한다. 벤젠 200㎖를 첨가하고 이어서 무수 탄산칼륨 10.0g을 첨가하고 실온으로 3시간 교반한후 여과한다. 감압하에서 벤젠 및 과잉된 파라알데히드를 유거한다. 잔류물에 에탄올을 첨가하면 결정화된다.Steryl-2,3-oxidoethylidene-4,6-ethylidene- D-glucopyranoside, sterilyl -D-glucopyranoside (steryl- extracted from soy lecithin) As -D-glucopyranoside, the sterol adjustment is 10.0 g of 60% cytosterol, 20% stigmasterol, and 20% camphorol) is added to 300 ml of fresco and 100 ml of paraaldehyde is added to give a suspension. Add one drop of concentrated sulfuric acid and stir to room temperature for 24 hours. 200 ml of benzene is added, followed by 10.0 g of anhydrous potassium carbonate, which is stirred for 3 hours at room temperature and then filtered. Benzene and excess paraaldehyde are distilled off under reduced pressure. The addition of ethanol to the residue crystallizes.
에탄올에서 재결정한바 융점 184-186℃의 목적한 화합물의 무색판상 결정으로서 7.5g 얻어졌다(수율 64.4%)When recrystallized from ethanol, 7.5g of colorless crystals of the desired compound having a melting point of 184-186 占 폚 were obtained (yield 64.4%).
원소분석치 C41H68O7로서Elemental Analysis C 41 H 68 O 7 As
계산치 C : 73.17 H : 10.19Calculated C: 73.17 H: 10.19
실측치 C : 72.90 H : 10.10Found C: 72.90 H: 10.10
MS m/e 672, 670,658(M+)MS m / e 672, 670,658 (M + )
[실시예 2]Example 2
코레스테릴-2,3-옥시드에틸리덴-4,6-에틸리덴--D-글루코피라노시드Coresteryl-2,3-oxideethylidene-4,6-ethylidene- -D-glucopyranoside
코레스테릴--D-글루코피라노시드 4.0g을 200㎖의 나스콜에 넣어, 파라알데히드 50㎖로 현탁시키고, 농황산 한 방울을 첨가하여 실온으로 24시감 교반한다. 이어서 실시예 1의 경우와 같이 후처리를 하고 조제의 결정 4.8g을 얻은다. 이것을 에탄올에서 재결정한바 융점 177-178℃의 목적한 화합물의 3.1g이 무색침전상결정으로서 얻어졌다(수율 66.0%).Coresteryl 4.0 g of -D-glucopyranoside was added to 200 ml of nascol, suspended with 50 ml of paraaldehyde, and a drop of concentrated sulfuric acid was added and stirred for 24 hours at room temperature. Subsequently, the same treatment as in Example 1 was carried out to obtain 4.8 g of the prepared crystal. When recrystallized from ethanol, 3.1 g of the target compound having a melting point of 177 to 178 ° C was obtained as colorless precipitated phase crystals (yield 66.0%).
원소분석치 C39H64O7로서Elemental Analysis C 39 H 64 O 7 As
계산치 C : 72.63 H : 10.00Calculation C: 72.63 H: 10.00
실측치 C : 72.53 H : 10.17Found C: 72.53 H: 10.17
[실시예 3]Example 3
-시토스테릴-2,3-옥시드에틸리덴-4,6--D-에릴리덴 글루코피라노시드 -Cytosteryl-2,3-oxideethylidene-4,6- -D-Elylidene glucopyranoside
-시토스테릴--D-글루코피라노시드 3.0g을 200㎖의 프라스코에 넣어서, 파라알데히드 50㎖로 현탁시키고, 농황산 한 방울을 첨가하여 실온으로 12시감 교반한다. 이어서 실시예 1의 경우와 같이 후처리를 하고, 조결정 3.0g을 얻는다. 이것을 에탄올에서 재결정한바 융점 184~186℃의 목적한 화합물 2.6g이 무색침상 결정으로 얻어졌다(수율 74.3%). -Sitosteryl- 3.0 g of -D-glucopyranoside was placed in 200 ml of fresco, suspended with 50 ml of paraaldehyde, and a drop of concentrated sulfuric acid was added and stirred at room temperature for 12 hours. Subsequently, post-treatment is performed as in the case of Example 1 to obtain 3.0 g of crude crystals. The crystals were recrystallized from ethanol to give 2.6 g of the target compound having a melting point of 184 to 186 캜 as colorless needles (yield 74.3%).
원소분석치 C41H68O7로서Elemental Analysis C 41 H 68 O 7 As
계산치 C : 73.17 H : 10.19Calculated C: 73.17 H: 10.19
실측치 C : 73.04 H : 10.16Found C: 73.04 H: 10.16
[실시예 4]Example 4
스테릴-2,3-옥시드메틸리덴-4,6-메틸리덴--D-글루코피라노시드. 스테릴--D-글루코시드(실시예 1의 경우와 같음) 10.0g을 300㎖의 프라스코에 넣어서, 파라포름 알데히드 10.0g과 벤젠 200㎖를 첨가하여 서현탁액으로 한다. 농황산 한 방울을 첨가하여 실온으로 24시간 교반한다. 그후 유거관을 붙여서 천천히 가온한다. 벤젠 유거에 따라서 반응이 진행된다. 균일한 용액으로 되었을 때 가열을 정지하고, 냉각시킨후 무수탄산칼륨 3.0g을 첨가하고 30분간 교반한다. 여과 후 감압으로 농축 건조시킨다. 벤젠에 용해시키고 칼람클로마토그래피(와코(和光)겔 C-200로 분리 정제한다. (벤젠/에테르 4 : 1 혼액으로 용출). 얻어진 미황색 분말을 에탄올에서 재결정하여 융점 160~162℃의 목적한 화합물 4.8g이 무색침상 결정으로서 얻어졌다(수율 43.9%)Steyl-2,3-oxidemethylidene-4,6-methylidene- -D-glucopyranoside. Steril 10.0 g of -D-glucoside (as in Example 1) is placed in 300 ml of fresco, and 10.0 g of paraformaldehyde and 200 ml of benzene are added to prepare a suspension. Add one drop of concentrated sulfuric acid and stir to room temperature for 24 hours. After that, attach the canister and warm it up slowly. The reaction proceeds with benzene distillation. When it became a uniform solution, heating was stopped, and after cooling, 3.0 g of anhydrous potassium carbonate was added and stirred for 30 minutes. After filtration, concentrated to dryness under reduced pressure. It is dissolved in benzene and separated and purified by column chromatography (Wako gel C-200., Eluted with benzene / ether 4: 1 mixture). 4.8 g of compound was obtained as colorless needles (yield 43.9%)
원소분석치 C38H62O7로서Elemental Analysis As C 38 H 62 O 7
계산치 C : 72.34 H : 9.91Calculated C: 72.34 H: 9.91
실측치 C : 72.21 H : 10.02Found C: 72.21 H: 10.02
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR7701265A KR810001047B1 (en) | 1977-05-28 | 1977-05-28 | Method for preparing cyclic acetal derivative of sterylglucoside |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR7701265A KR810001047B1 (en) | 1977-05-28 | 1977-05-28 | Method for preparing cyclic acetal derivative of sterylglucoside |
Publications (1)
Publication Number | Publication Date |
---|---|
KR810001047B1 true KR810001047B1 (en) | 1981-09-07 |
Family
ID=19204400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR7701265A Expired KR810001047B1 (en) | 1977-05-28 | 1977-05-28 | Method for preparing cyclic acetal derivative of sterylglucoside |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR810001047B1 (en) |
-
1977
- 1977-05-28 KR KR7701265A patent/KR810001047B1/en not_active Expired
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU902666A3 (en) | Method of preparing pleuromutiline glycoside derivatives | |
DE2750812C2 (en) | 4-alkoxy-4-desmethoxydaunomycins and process for their preparation | |
IL25493A (en) | Pregnano(17alpha,16alpha-d)oxazolines | |
KR810001047B1 (en) | Method for preparing cyclic acetal derivative of sterylglucoside | |
DE3887212T2 (en) | Process for the preparation of derivatives of 6,7-diazyl-7-deacetylforskolin. | |
US4257949A (en) | Bisnoraldehyde-22-enamine process | |
KR900000266B1 (en) | Method for preparing ethyl ester of apovincaminic acid | |
US4849512A (en) | 3-acylamino-3-deoxyallose derivatives | |
JPS5831359B2 (en) | Cyclic acetal derivative of steryl glucoside | |
US4174451A (en) | 2-Furyl-(3,4-dimethyl-2-pyridyl)-carbinol | |
KR820001263B1 (en) | Process of preparing for steryl gluco-side acetal derivatives | |
US3025309A (en) | Delta2-androstene and etiocholene compounds and process for preparing same | |
KR800001451B1 (en) | Process for the preparation of 1,3,5-trisubstitude benzene derivative | |
JPS5831358B2 (en) | Acetal derivatives of steryl glucosides | |
KR820002232B1 (en) | Triamcynolone acetonide esters and preparation thereof | |
JPS58116500A (en) | Sterol derivative | |
US2881170A (en) | Tropaminone compounds and a process of making same | |
JP2905931B2 (en) | Process for producing optically active 2-cyclopentenones | |
JP2513222B2 (en) | Novel pyrimidine derivative | |
SU455960A1 (en) | Method for preparing 4-bromomethylthiazolin-2-one | |
KR790001684B1 (en) | Process for the preparation of 5-benzyl picolinic acids | |
HU193454B (en) | Process for producing 3-phenyl-butyraldehyde derivatives | |
US3102122A (en) | Process of preparing griseofulvic acid | |
KR800001450B1 (en) | Method for preparing 1, 3, 5-trisubstituted benzene derivative | |
US3264285A (en) | Novel 19-nor-testosterone-17-hemiacetals and -hemiacetal esters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
PG1605 | Publication of application before grant of patent |
St.27 status event code: A-2-2-Q10-Q13-nap-PG1605 |
|
PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U11-oth-PR1002 Fee payment year number: 1 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 19880908 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 19880908 |
|
P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |